AVNS VS SNDX Stock Comparison
Performance
AVNS10/100
10/100
AVNS returned -19.03% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
SNDX10/100
10/100
SNDX returned -33.90% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.
Sentiment
AVNS86/100
86/100
AVNS had a bullish sentiment score of 85.83% across Twitter and StockTwits over the last 12 months. It had an average of 1.00 posts, 0.00 comments, and 0.00 likes per day.
SNDX74/100
74/100
SNDX had a bullish sentiment score of 73.61% across Twitter and StockTwits over the last 12 months. It had an average of 5.00 posts, 1.29 comments, and 3.63 likes per day.
Technicals
AVNS61/100
61/100
AVNS receives a 60 of 100 based on 14 indicators. 8 are bullish, 5 are bearish.
SNDX64/100
64/100
SNDX receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.
Earnings
AVNS10/100
10/100
AVNS has missed earnings 6 times in the last 20 quarters.
SNDX57/100
57/100
SNDX has missed earnings 4 times in the last 20 quarters.
Profit
AVNS46/100
46/100
Out of the last 20 quarters, AVNS has had 8 profitable quarters and has increased their profits year over year on 7 of them.
SNDX10/100
10/100
Out of the last 20 quarters, SNDX has had 1 profitable quarters and has increased their profits year over year on 1 of them.
Volatility
AVNS46/100
46/100
AVNS has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.
SNDX42/100
42/100
SNDX has had a lower than average amount of volatility over the last 12 months giving it a score of 41 of 100.
Analyst Price Targets
AVNS
"Analyst Price Targets" not found for AVNS
SNDX88/100
88/100
8 analysts offer 12-month price targets for SNDX. Together, they have an average target of 37.67, the most optimistic target put SNDX at 41 within 12-months and the most pessimistic has SNDX at 33.
All score calculations are broken down here to help you make more informed investing decisions
Avanos Medical, Inc. Summary
New York Stock Exchange / AVNS
Healthcare
Medical - Devices
Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Syndax Pharmaceuticals, Inc. Summary
Nasdaq / SNDX
Healthcare
Biotechnology
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare AVNS to other companies in the same or a similar industry.